Late-Stage Clinical Company
Validating Small Molecule Ophthalmics: Transport Expertise Driving NDA Approval
Challenge
A late-stage clinical company committed to developing innovative ophthalmic pharmaceutical products aimed at improving vision was preparing for regulatory filing for a New Drug Application (NDA). Their lead product was designed to restore near vision loss due to presbyopia. As the company approached the NDA submission, they required thorough and robust transport validation to demonstrate product stability and integrity throughout their supply chain. Recognizing Modality Solutions’ proven track record from previous successful projects in transport validation, they reached out for assistance in this critical area.
Objectives
- Comprehensive Risk Management: Assessing and mitigating risks across the entire supply chain.
- Robust Validation Strategy: Developing detailed validation plans and executing rigorous shipping qualification studies.
- Advanced Packaging Solutions: Selecting and qualifying thermal packaging to protect product integrity during transport.
- Thermal Stability Assurance: Precisely defining allowable temperature ranges and demonstrating extended product stability.
- Regulatory Excellence: Effectively managing FDA interactions and thoroughly documenting validation outcomes for a successful NDA filing.
Results
The product is expected to receive regulatory approval soon, incorporating the comprehensive transport validation data generated through Modality Solutions’ rigorous testing. Specifically, the extensive thermal exposure data supporting stability at prolonged elevated temperatures significantly enhances the regulatory submission, optimizing the product’s market entry readiness and long-term commercial success.
Download the full case study